DuChemBIO Co.,Ltd.
Financials
Valuation Metrics
DuChemBIO Co.,Ltd.'s Market Cap is ₩1866B. At end of 2025 it was ₩2712B. Ranked #862 of 2,436 in KR market (top 35%), #399 of 1,649 on KOSDAQ (top 24%), #28 of 96 in Health Care Equipment & Services (top 29%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 186.60B KRW | KR#862/2,436 Sec#28/96 |
| Revenue | 39.82B KRW | KR#1,901/2,436 Sec#54/96 |
| Net Income | 6.97B KRW | KR#1,022/2,436 Sec#31/96 |
| Total Assets | 77.20B KRW | KR#1,928/2,436 Sec#61/96 |
| Net Assets | 50.11B KRW | KR#1,876/2,436 Sec#59/96 |
| Employees | 141 | KR#1,362/2,436 Sec#46/96 |
| Value | ||
| P/E | 26.75x | KR#1,210/2,436 Sec#37/96 |
| P/B | 3.72x | KR#2,179/2,436 Sec#80/96 |
| PEG | 0.20x | KR#529/2,436 Sec#18/96 |
| P/S | 4.69x | KR#2,125/2,436 Sec#71/96 |
| EV/EBITDA | 21.88x | KR#1,059/2,436 Sec#33/96 |
| FCF Yield | 4.86% | KR#876/2,436 Sec#23/96 |
| Profitability | ||
| ROE | 13.92% | KR#285/2,436 Sec#13/96 |
| ROA | 9.03% | KR#255/2,436 Sec#16/96 |
| Op. Margin | 20.17% | KR#149/2,436 Sec#14/96 |
| Revenue Growth | 14.72% | KR#758/2,436 Sec#34/96 |
| Earnings Growth | 130.99% | KR#350/2,436 Sec#14/96 |
| Financial Health | ||
| Debt Ratio | 154.06% | KR#1,245/2,436 Sec#66/96 |
| Total Debt | 5.94B KRW | KR#1,752/2,436 Sec#63/96 |
| FCF | 9.07B KRW | KR#735/2,436 Sec#19/96 |
| Cash | 16.82B KRW | KR#1,351/2,436 Sec#39/96 |
| Current Ratio | 1.69x | KR#1,155/2,436 Sec#64/96 |
| Net Debt/EBITDA | -1.35x | KR#392/2,436 Sec#12/96 |
| Performance | ||
| 1Y Return | -37.91% | KR#1,789/2,436 Sec#62/96 |
| 1M Return | 4.97% | KR#474/2,436 Sec#24/96 |
| From 52W High | -48.71% | KR#1,132/2,436 Sec#42/96 |
| 1Y MDD | -53.42% | KR#1,085/2,436 Sec#38/96 |
| Trading | ||
| Volume | 74,734 shares | KR#1,104/2,436 Sec#47/96 |
| Foreign Own. | 0.96% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | 245 KRW | KR#1,155/2,436 Sec#36/96 |
| BPS | 1,768 KRW | KR#2,095/2,436 Sec#71/96 |
Company Info
DuChemBio was established in 2002 for the development, manufacturing, and sales of radiopharmaceuticals for cancer and brain disease diagnosis and treatment, completing its KOSDAQ transfer listing in 2024. The company holds the largest number of PET-CT pharmaceuticals in Korea and operates 12 GMP-certified manufacturing facilities, achieving the top market share in major product categories. With a "First-in-Class" strategy for diagnostics and "Best-in-Class" for therapeutics, DuChemBio is striving to become a specialized radiopharmaceutical platform company in Asia. DuChemBio was established in 2002 and is headquartered in Mapo-gu, Seoul.